Jill Donaldson

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*

Ángel Crespo López, José A. Lorente, Jay S. Steingrub et al. · Critical Care Medicine · 2004 · 917 citations

Administration of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)*

Jan Bakker, Robert F. Grover, Angela McLuckie et al. · Critical Care Medicine · 2004 · 194 citations

Nitric Oxide Synthase Inhibition: A New Principle in the Treatment of Migraine Attacks

LH Lassen, Messoud Ashina, I Christiansen et al. · Cephalalgia · 1998 · 163 citations

Spontaneous Migraine Attacks, Single Migraine Attack, Medicinal Chemistry +12

Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)*

David I. Watson, Robert F. Grover, Antonio Anzueto et al. · Critical Care Medicine · 2004 · 129 citations